MUNICH, Germany and
SAN DIEGO, Calif., Feb. 12, 2015 /PRNewswire/ -- ResMed
(NYSE:RMD) today announced that the Munich District Court upheld its injunction
against Chinese medical device manufacturer BMC Medical Co., Ltd.
(BMC). The injunction prohibits BMC from offering, selling or
distributing infringing mask products in Germany.
The Munich Court's preliminary
injunction decision, first rendered in November 2013, and continued in place today,
found that respiratory mask assemblies such as BMC's Willow and
FeaLite nasal pillow masks infringe ResMed's European patent EP
1356842.
As a result, BMC will not be permitted to offer, sell or
distribute the infringing products in Germany at least until the German Federal
Patent Court eventually addresses BMC's challenges to the validity
of the patent.
The German decision follows a similar ruling made in
December 2014 by the International
Trade Commission (ITC) in the United
States, which found several BMC masks infringe a number of
ResMed's U.S. patents.
"The judge's decision is another victory for ResMed and patients
everywhere who deserve high-quality, comfortable products to treat
their sleep and respiratory conditions," said David Pendarvis, ResMed chief administrative
officer and global general counsel. "We will continue to defend our
innovations and pursue all legal remedies to prevent infringement
in any country where it may exist."
About ResMed
ResMed changes lives by developing,
manufacturing and distributing medical equipment for treating,
diagnosing, and managing sleep-disordered breathing, chronic
obstructive pulmonary disease, and other chronic diseases. We
develop innovative products and solutions to improve the health and
quality of life of those who suffer from these conditions, and we
work to raise awareness of the potentially serious health
consequences of untreated sleep-disordered breathing. For more
information on ResMed, visit www.resmed.com.
ResMed
Contacts:
|
|
For News
Media
|
For
Investors
|
Alison
Graves
|
Agnes
Lee
|
Global Corporate
Communications
|
Senior Director,
Investor Relations
|
O:
858-836-6789
|
O:
858-836-5971
|
news@resmed.com
|
investorrelations@resmed.com
|
Logo -
http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/resmed-wins-continued-injunction-against-bmc-in-german-patent-infringement-action-300035622.html
SOURCE ResMed Inc.